|
29 Oct 2009 |
YM BIOSCIENCES REPORTS ADDITIONAL RESULTS FROM NIMOTUZUMAB PHASE III STUDY IN CHILDREN WITH GLIOMA PRESENTED BY ONCOSCIENCE AG
|
|
28 Oct 2009 |
ThromboGenics and BioInvent Complete Patient Recruitment of Phase II DVT Prophylaxis Study with Anti-Factor VIII (TB-402)
|
|
28 Oct 2009 |
Novartis biological drug Ilaris® approved in EU to treat children and adults with CAPS, a rare debilitating auto-inflammatory disease
|
|
28 Oct 2009 |
Morphotek(R), Inc. Announces a Licensing Deal With Centocor Ortho Biotech Inc. for Exclusive Development and Commercialization Rights for a Therapeutic Monoclonal Antibody
|
|
27 Oct 2009 |
Champions Biotechnology, Inc. Signs Exclusive Licensing Agreement with Ramot for TAR-1, a Novel Therapeutic for the Treatment of Cancer
|
|
27 Oct 2009 |
Vivalis Expands Agreement With Sanofi-Aventis in the Therapeutic Proteins Field
|
|
27 Oct 2009 |
GSK and Genmab receive accelerated approval for Arzerra
|
|
26 Oct 2009 |
Astellas to Terminate the Development of Anti-Human Osteopontin Antibody ASK8007for RA
|
|
23 Oct 2009 |
Halozyme Announces Roche Doses First Patient in Phase 3 Clinical Trial with Subcutaneous Herceptin(R)
|
|
21 Oct 2009 |
Tolerx Presents Otelixizumab Phase 2 Dose Optimization Data At The IDF's 20th World Diabetes Congress
|
|
21 Oct 2009 |
BioWa and NKTT Announce Licensing of BioWa's POTELLIGENT(R) Technology For Use in Antibody Research and Development
|
|
21 Oct 2009 |
Peregrine Pharmaceuticals Reports 61% Objective Response Rate in 46-Patient Bavituximab Phase II Trial in Advanced Breast Cancer
|
|
20 Oct 2009 |
Crucell Rabies Monoclonal Antibody Combination: Positive Results Philippines Phase II Study Presented at RITA Conference
|
|
20 Oct 2009 |
MorphoSys and Daiichi Sankyo Forge Alliance to Develop Novel Antibody Therapies against Hospital-Acquired Infections
|
|
20 Oct 2009 |
GlaxoSmithKline and Human Genome Sciences announce full presentation at ACR of positive phase 3 study results for BENLYSTA in systemic lupus erythematosus
|
|
20 Oct 2009 |
New Phase II data show ACZ885 gave better pain relief and flare prevention for patients with chronic gout than an injectable corticosteroid
|
|
20 Oct 2009 |
XOMA Presents First XOMA 052 Cardiovascular Disease Animal Model Results
|
|
19 Oct 2009 |
Amgen Provides Update on Status of Prolia(TM) (Denosumab) Biologics License Application (BLA) Submitted to the U.S. Food and Drug Administration (FDA)
|
|
19 Oct 2009 |
New SIMPONI(TM) Data Show Long-Term Efficacy in Treatment of Rheumatoid Arthritis
|
|
19 Oct 2009 |
Trubion Pharmaceuticals, Inc. Reports Positive Data from Phase 2b Re-treatment Study of TRU-015
|
|
19 Oct 2009 |
ORENCIA® (abatacept) Demonstrated Sustained Clinical Response in a Study of Adult Patients with Moderate to Severe Early Rheumatoid Arthritis (Less Than Two Years Duration)
|
|
19 Oct 2009 |
Phase III Study Showed Two Years of ACTEMRA ® (tocilizumab) Inhibited Progression of Joint Damage and Improved Disease Remission
|
|
19 Oct 2009 |
ABLYNX PROVIDES AN R&D UPDATE AND ANNOUNCES RECENT TECHNOLOGY ADVANCES
|
|
17 Oct 2009 |
Genentech and Biogen Idec Receive a Complete Response from FDA for Earlier Use of Rituxan for Rheumatoid Arthritis
|
|
17 Oct 2009 |
UCB's Cimzia(R) (certolizumab pegol), Shows Rapid and Sustained Clinical Response in Adult Patients Living with Moderate to Severe Rheumatoid Arthritis
|
